LB Pharmaceuticals, Inc. (LBRX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$40.85+1.29%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · LBRX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | |
|---|---|---|---|---|
| Operating Expenses & Income | ||||
| R&D Expenses | 69.7 | 16.7 | 51.2 | — |
| Operating Income | — | — | (63.1) | — |
| Earnings from Continuing Operations | ||||
| Interest & Investment Income | 9.3 | 3.9 | 1.7 | — |
| Other Non-Operating Income / Expenses | 9.5 | 5.2 | 1.7 | — |
| EBT, Incl. Unusual Items | (85.7) | (25.2) | (63.1) | — |
| Income Tax Expense | — | 0.0 | 0.0 | — |
| Net Income | ||||
| Net Income | (85.7) | (25.2) | (63.1) | — |
| Per Share | ||||
| Basic EPS | (2.84) | (3.13) | (176.15) | — |
| Diluted EPS | (2.84) | (3.13) | (176.15) | — |
| Basic Weighted Avg Shares | 30.1 | 8.0 | 0.4 | — |
| Diluted Weighted Avg Shares | 30.1 | 8.0 | 0.4 | — |
| Supplemental | ||||
| EBITDA | — | — | (63.0) | — |
| EBIT | — | — | (63.1) | — |
| Effective Tax Rate | — | — | -0.0% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.